• Humana’s CenterWell has acquired MaxHealth, a primary care provider in Florida.
• The deal significantly broadens CenterWell’s primary care presence across the state.
• The acquisition supports Humana’s value based care model for Medicare and other patients.

For investors watching NYSE:HUM, this move comes with the stock trading around $184.99 and showing mixed recent performance. Shares are up 2.0% over the past week but have seen declines of 32.3% over 30 days and 30.1% year to date. Over longer periods, returns have also been weak, with a 27.1% decline over 1 year and deeper pullbacks across 3 and 5 years.

The MaxHealth deal aligns with Humana’s focus on primary care and value based arrangements, and it results in a larger footprint in a key Medicare market such as Florida. For investors, the development raises questions about how this expanded network could affect patient volumes, care coordination, and Humana’s differentiation relative to other managed care peers over time.

Stay updated on the most important news stories for Humana by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Humana.

Quick Assessment

• ✅ Price vs Analyst Target: At US$184.99, Humana trades about 19.6% below the US$230.25 analyst price target.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading at 81.8% below fair value, flagged as undervalued.
• ❌ Recent Momentum: The 30 day return of 32.3% decline reflects weak recent sentiment despite the MaxHealth news.

There is only one way to know the right time to buy, sell or hold Humana. Head to Simply Wall St's company report for the latest analysis of Humana's Fair Value.

Key Considerations

• 📊 The MaxHealth acquisition expands CenterWell’s Florida primary care footprint, which could be important for Humana’s value based care model and Medicare positioning.
• 📊 Watch how management talks about integration costs, patient retention and primary care utilization, as well as whether revenue and net income stay aligned with the current P/E of 18.8.
• ⚠️ One flagged issue is that the 1.91% dividend is not well covered by free cash flows, so income focused investors may want to check how capital is allocated after this deal.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Humana analysis. Alternatively, you can visit the community page for Humana to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.